Our Mission
TrippBio, Inc. (“TrippBio”) was created to develop and commercialize broad spectrum anti-virals with low side effect profiles that are shown to be effective against multiple respiratory viruses. Our first therapeutic – TD213 – is a low cost medication that has been in use for decades. It has an outstanding safety record and has demonstrated positive results for SARS-CoV-2, influenza and respiratory syncytial virus (RSV).
Because TD213 is a repurposed drug, the development time, expense, and risk of drug development has been significantly reduced. We anticipate that TD213 will be an inexpensive oral drug, the production of which can be rapidly accelerated.
TD213 is based on years of anti-viral research by Dr. Ralph Tripp, Professor and Georgia Research Alliance Chair in Vaccines and Therapeutics at the University of Georgia.
Dr. Tripp was a section chief at the CDC working on SARS-CoV and other respiratory viruses in Atlanta from 2004 – 2009 before recruited to the University of Georgia. Dr. Tripp was also on the FDA Advisory Committee that voted to approve the Emergency Use Authorization of the Pfizer-BioNTech COVID-19 vaccine on
December 10, 2020.
1
Who we are
TrippBio is a new biotechnology company dedicated to the discovery of treatments for infectious diseases with a specialization in emerging respiratory viruses.
2
Area of focus
TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to treat viral pathogens like influenza, RSV and COVID-19.
3
Advancement in testing
TD213 is currently in an advanced phase of testing, This drug is showing great potential and if proven successful, could be a unique mechanism of action to help millions.
Why us
Our story
- Dr. Tripp partnered with SpinUp Campus to seek funding and the launch of TrippBio and TD213 to an eager audience.
- TrippBio signed a worldwide, exclusive, intellectual property license agreement in all fields-of-use with the non-profit University of Georgia Research Foundation.
- TrippBio plans to implement a clinical program immediately to determine the efficacy of TD213 against influenza, RSV and COVID-10.
Invest in our vision
Get to know us by checking out the videos below
Introducing TrippBio
We focuses on developing innovative applications of existing drugs with low risk and high efficacy to prevent and treat rogue viruses, starting with SARS-CoV-2, the virus that causes COVID-19.
- Same- or next-day appointments
- Personal membership
- On-site lab services
How it works
Get to know what the virus does and how it impacts the body. What we at TrippBio is doing to come up with a solution.
- Virtual urgent care
- Virtual primary care
- Virtual mental health
Our Team
Billy Meadow
Chairman
David E. Martin
President & CEO
Dr. Ralph A. Tripp
Chief Science Officer
